TheraRadar

Aldeyra

Pre-Approval PRO BETA
35
Total Trials
14
Phase 3
22
Phase 2
1
Recruiting
400
Score

Pipeline by Phase

Phase 3
14
Phase 2
22
Phase 1
3

Therapeutic Focus

Dry Eye Allergic Conjunctivitis Dry Eye Disease Dry Eye Syndromes Conjunctivitis, Allergic

Clinical Trials (35)

NCT07402876 Phase 3 RECRUITING

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Started: 2/1/2026

NCT06493604 Phase 3 COMPLETED

A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Started: 6/24/2024

NCT04735393 Phase 3 COMPLETED

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Started: 1/26/2021

NCT06424444 Phase 3 COMPLETED

A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Started: 4/29/2024

NCT04136366 Phase 3 COMPLETED

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Started: 11/15/2019

NCT06389214 Phase 3 COMPLETED

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Started: 4/9/2024

NCT05062330 Phase 3 COMPLETED

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Started: 8/28/2021

NCT03494504 Phase 3 COMPLETED

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Started: 3/30/2018

NCT03131154 Phase 3 COMPLETED

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Started: 4/26/2017

NCT03879863 Phase 3 COMPLETED

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Started: 4/16/2019

NCT04207736 Phase 3 COMPLETED

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Started: 12/5/2019

NCT05234554 Phase 3 COMPLETED

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Started: 1/21/2022

NCT03445650 Phase 3 COMPLETED

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Started: 7/18/2018

NCT06685692 Phase 2 COMPLETED

A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)

Started: 11/4/2024

NCT04674358 Phase 2 COMPLETED

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Started: 11/21/2020

NCT04908514 Phase 2 COMPLETED

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Started: 5/7/2021

NCT03916042 Phase 2 COMPLETED

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Started: 4/23/2019

NCT05392192 Phase 2 COMPLETED

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Started: 4/7/2022

NCT05102409 Phase 2 COMPLETED

An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber

Started: 9/9/2021

NCT04971031 Phase 2 COMPLETED

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Started: 6/15/2021

NCT04847544 Phase 2 COMPLETED

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Started: 3/31/2021

NCT04728711 Phase 2 COMPLETED

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Started: 1/9/2021

NCT03404115 Phase 2 COMPLETED

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Started: 1/2/2018

NCT03162783 Phase 2 COMPLETED

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Started: 5/15/2017

NCT05424549 Phase 2 COMPLETED

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Started: 3/9/2022

NCT05717920 Phase 2 COMPLETED

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Started: 2/15/2023

NCT05392179 Phase 2 COMPLETED

A Study in Subjects With Retinitis Pigmentosa

Started: 7/14/2022

NCT05599815 Phase 2 WITHDRAWN

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Started: 1/1/2023

NCT02578914 Phase 2 COMPLETED

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Started: 8/1/2015

NCT02406209 Phase 2 COMPLETED

A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Started: 3/1/2015

NCT03012165 Phase 2 COMPLETED

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Started: 12/1/2016

NCT02402309 Phase 2 COMPLETED

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

Started: 3/1/2015

NCT03660878 Phase 1 COMPLETED

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Started: 9/8/2018

NCT05487404 Phase 1 COMPLETED

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

Started: 11/15/2021

NCT03709121 Phase 1 COMPLETED

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Started: 10/2/2018

Drug Candidates

ICM ADX-2191 injection Monthly ADX-2191 injection Reproxalap Ophthalmic Solution (0.25%) Vehicle Ophthalmic Solution ADX-629 Placebo Comparator Reproxalap ophthalmic solution (0.25%) Vehicle ophthalmic solution ADX-2191 (intravitreal methotrexate 0.8%) Reproxalap Ophthalmic Solution (0.5%)
Activity Status: Active
Last Trial Started: 2/1/2026
Last Trial Ended: 6/18/2025
Trials (12 months): 1
Completed Trials: 33
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.